|
FibroTest, known as FibroSure in the US, is a patented biomarker test that uses the results of six blood serum tests to generate a score that is correlated with the degree of liver damage in people with a variety of liver diseases. FibroTest has the same prognostic value as a liver biopsy. FibroTest has been evaluated in relation to liver biopsy (the current reference standard in liver disease assessment) in a large number of patients with hepatitis C,〔 hepatitis B,〔 alcoholic liver disease,〔 Non-alcoholic fatty liver disease〔 and in the general population. By 2008 it had been used in over 350,000 patients. FibroTest has been validated for the initial diagnosis of fibrosis, but also for the monitoring of patients. In 2006, the French National Authority for Health recommended the use of FibroTest as a first-line assessment tool for fibrosis with untreated chronic hepatitis C.〔(Publication of 'Haute Autorité de Santé' (fr) )〕 ==Procedure== The FibroTest score is calculated from the results of a six-parameter blood test, combining six serum markers with the age and gender of the patient: Alpha-2-macroglobulin, Haptoglobin, Apolipoprotein A1, Gamma-glutamyl transpeptidase (GGT), Total bilirubin, and Alanine transaminase (ALT). ALT is used in a second assessment called ActiTest that is part of FibroTest. The equation for calculating the FibroTest score regression coefficient (logistic regression) is:〔(U.S. patent 6,631,330 )〕 : Due to variability of components assays and analyzers, FibroTest assays can only be performed in validated laboratories. FibroTest cannot be used without algorithms that detects false positives and false negatives; the equation alone is not a diagnosis tool. The laboratory or physician connects to the BioPredictive website〔(FibroTest website )〕 for calculation of the test results and prints the results sheet, which is available immediately and is accompanied by an interpretation aid and precautions for use. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「FibroTest」の詳細全文を読む スポンサード リンク
|